Building Launch Marketing Assets That Pass MFDS Review

Where Marketing Hits the Regulatory Wall

A common pattern for foreign medical device manufacturers entering Korea: regulatory approval lands, the commercial team activates marketing assets translated from the US or EU launch materials, and within weeks the materials are flagged by the Korean Medical Device Advertising Self-Regulatory Body (KMDIA) or — worse — by MFDS itself. The launch slows. Hospitals delay decisions. The launch team blames the regulatory consultant; the regulatory team points out that they were never asked about the marketing assets.

The gap is structural. Korean medical device advertising regulation is not lighter than US/EU; it is stricter in several specific ways. And it is regulated by a different body than device approval (KMDIA + MFDS for promotional content; MFDS alone for labeling), so the approval process for marketing materials runs in parallel with the device approval process, not after it.

What Counts as Regulated Advertising

In Korea, "advertising" for medical devices includes:

• Brochures, sales sheets, and product catalogs
• Website pages describing the product
• Trade show booth content
• Social media posts about the product
• Sponsored content in medical journals
• Sales rep visual aids and detail aids
• Conference presentations (when sponsored or branded)
• Patient-facing materials (where the device has direct patient awareness)

Marketing materials that reference performance claims, comparative claims, indications, or images of clinical use are subject to pre-publication review. Internal sales training materials, scientific publications by independent researchers, and pure brand materials (logos, taglines, company introduction without product-specific claims) are typically out of scope.

Three Regulatory Constraints That Catch US/EU Marketers

Constraint 1: Comparative Claims Are Tightly Regulated

Korean advertising rules prohibit:

• Comparative claims against named competitors (even if true)
• Superlative claims ("best," "leading," "fastest") without independently verifiable evidence
• Performance comparisons referencing percentages that cannot be directly substantiated by submission-grade evidence

US marketing freely uses "30% faster than the leading alternative." Korean marketing cannot use this language even with citations. The fix is to reframe claims as absolute statements ("processes 200 cases per hour") rather than relative comparisons.

Constraint 2: Clinical Imagery Has Special Rules

Images of clinical use — surgical procedures, patient interactions, anatomical illustrations — are subject to additional rules:

• Patient identity must not be inferable (no recognizable features even with face obscured if other identifying context is present).
• Surgical imagery requires the procedure to actually occur as shown (no staged composites).
• Anatomical illustrations must be accurate to clinical reality.
• Before/after imagery for diagnostic or imaging products has specific protocols around consistency of patient positioning and imaging parameters.

US marketing materials frequently use stock anatomical art that does not strictly conform; Korean review will flag these.

Constraint 3: HCP-Targeted vs Patient-Facing Materials Have Different Rules

Materials targeted at healthcare professionals (HCPs) — surgeons, nurses, technologists — operate under one set of rules. Patient-facing materials operate under a stricter set that prohibits direct promotional language and requires balanced presentation including risks and limitations.

The same product page on a website may need two variants: an HCP-portal version (technical, performance-focused) and a public-facing version (educational, risk-balanced). US-style direct-to-consumer pharmaceutical advertising is not the model; the Korean rules sit between EU restraint and the lighter US framework.

The Pre-Launch Asset Set

Marketing teams launching in Korea typically need these assets, all of which require regulatory review:

1. Korean product brochure (HCP version) — 4–8 pages, structured presentation with cited evidence.
2. Korean product brochure (patient-facing version) — 2–4 pages, balanced, education-focused.
3. Korean website pages — typically 1 product overview, 1 detailed specifications, 1 evidence/citations page.
4. Detail aid for sales reps — 6–10 page visual aid for in-clinic presentations to HCPs.
5. Conference materials — booth content, podium presentations, trade show handouts.
6. Trade journal advertisements (if part of the launch plan).

For a Class II product, this asset set is typically 30–50 hours of marketing copywriting + 10–20 hours of regulatory review + 1–2 rounds of revisions before the KMDIA submission. A 6–8 week timeline from brief to approved assets is realistic.

How Labeling and Marketing Diverge

Labeling and marketing are governed by different rules but share content sources:

• The IFU has the canonical indications, contraindications, warnings, and precautions.
• Marketing materials must align with the IFU and not extend claims beyond what is labeled.
• The IFU is reviewed by MFDS at device submission; marketing is reviewed separately by KMDIA and (for certain content) MFDS pre-publication review.

A common error: marketing materials drafted in parallel with the IFU drift slightly in language, ending up with claims that are nearly-but-not-quite consistent with labeled indications. The fix is to draft marketing materials referencing the IFU directly and to have the labeling and marketing teams reconcile during pre-launch review.

The Lean Approach to Marketing Asset Production

For manufacturers running multi-region launches, the cost-per-region of marketing assets compounds quickly. Lean principles applied to marketing asset production:

1. Modular content library. Same as for IFUs — write each claim, each indication summary, each piece of clinical evidence once, in a structured library. Per-region marketing materials draw from the library with translation.

2. Region-specific layer, not full rewrite. Korean materials need Korean-specific compliance language (KMDIA approval number, distributor information, MFDS notification number) but can share the underlying claims, imagery, and evidence with global materials.

3. Pre-translation regulatory review. Have the source language assets pre-reviewed for cross-jurisdictional compliance before translation begins. Fixing a non-compliant claim costs once at source; fixing it in 5 translated languages costs 5×.

Where Leanabl Plugs In

The Marketing Assets service runs the full marketing asset development for Korean launches — from KMDIA-compliant copywriting through pre-publication review submission. For broader commercial readiness covering launch, distribution, and HCP engagement, Commercial Operations carries the work post-approval. Labeling content that anchors marketing claims runs through the Labeling service.